Who are KOCITAF's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): COVAX only (1st and 2nd dose), Comirnaty Original/Omicron BA.4-5, Ad26.COV2.S vaccine, CCP, Novavax recombinant protein vaccine, Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/kocitaf.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

KOCITAF — Competitive Intelligence Brief

KOCITAF (KOCITAF) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral. Area: Infectious Disease.

phase 3 Antiviral SARS-CoV-2 spike protein Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

KOCITAF (KOCITAF) — Professor Francois Venter. KOCITAF is a small molecule drug that targets the SARS-CoV-2 virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
KOCITAF TARGET	KOCITAF	Professor Francois Venter	phase 3	Antiviral	SARS-CoV-2 spike protein
COVAX only (1st and 2nd dose)	COVAX only (1st and 2nd dose)	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
Comirnaty Original/Omicron BA.4-5	Comirnaty Original/Omicron BA.4-5	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.4-5 variants)
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein
CCP	CCP	Metro Infectious Disease Consultants	marketed	Convalescent plasma	SARS-CoV-2 spike protein and other viral antigens
Novavax recombinant protein vaccine	Novavax recombinant protein vaccine	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Recombinant protein vaccine	Viral surface antigens (e.g., SARS-CoV-2 spike protein)
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)	tozinameran-bnt162b2-riltozinameran-bnt162b2-omi-ba-1	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral class)

Ain Shams University · 1 drug in this class
Arbutus Biopharma Corporation · 1 drug in this class
Australasian Gastro-Intestinal Trials Group · 1 drug in this class
Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
Invivyd, Inc. · 1 drug in this class
JW Pharmaceutical · 1 drug in this class
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
Pfizer · 1 drug in this class
Professor Francois Venter · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KOCITAF — Competitive Intelligence Brief. https://druglandscape.com/ci/kocitaf. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab